PIA
RCKT icon

Piedmont Investment Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Piedmont Investment Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-362
Closed -$7K – 1991
2018
Q2 		$7K Buy
+362
New +$6.85K ﹤0.01% 1987

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Piedmont Investment Advisors's RCKT Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q3 2018, closing a stake of 362 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in RCKT in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 84 funds tracked by Wall St. Rank hold RCKT as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Rocket Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 362 Rocket Pharmaceuticals shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Rocket Pharmaceuticals position peaked at $7K in Q2 2018.
  • 84 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.